Ot­su­ka’s AD­HD as­set suc­ceeds in reg­is­tra­tional tri­als with chil­dren and teens

Ot­su­ka Phar­ma­ceu­ti­cal’s AD­HD drug can­di­date has met its goal in a pair of Phase III tri­als fo­cused on chil­dren and teens with the neu­rode­vel­op­men­tal con­di­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER